Drugs / PIPENDOXIFENE
PIPENDOXIFENE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00006369 | Jun 2000 → ? | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIPENDOXIFENE | ChEMBL registry synonym — accepted as the source's own label CHEMBL44426 ↗ |
| Known as | ERA-923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006369 ↗ |
| Known as | Pipendoxifeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL44426 ↗ |
| Modality | Small molecule | — CHEMBL44426 ↗ |
| Route | Oral | “Patients receive oral ERA-923 daily” NCT00006369 ↗ |